BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

VolverVolver

Resultados 47 resultados LastUpdate Última actualización 01/02/2023 [12:51:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 2 nextPage   por página


Method For Diagnosing Alzheimer's Disease Spectrum Neurocognitive Disorders From Tear Sample, And Solution And Diagnostic Kit Useful In The Method

NºPublicación: US2023024661A1 26/01/2023

Solicitante:

UNIV SZEGEDI [HU]

WO_2021130508_A2

Resumen de: US2023024661A1

The invention relates to an aqueous solution of AuCl3×2H2O or HAuCl4×4H2O, ZnCl2 or ZnSO4, and AgNO3 having an Au3+ concentration of 0.8 mM-1.6 mM, a Zn2+ concentration of 15 μM-50 μM, and an Ag+ concentration of 5 μM-50 μM. The invention extends to a kit comprising a solution of the invention, a method of preparing said solution, and the use of a solution of the invention, a solution prepared by a method of the invention, or a kit of the invention in predicting and/or diagnosing and/or monitoring a neurocognitive disorder of the Alzheimer's disease spectrum. The invention extends to a method for predicting and/or diagnosing and/or monitoring a neurocognitive disorder of the Alzheimer's disease spectrum in a patient comprising contacting a tear sample from the patient normalised for protein concentration with a solution of the invention; applying an amount of the tear sample thus obtained to a surface; allowing the tear sample to dry; and drawing a conclusion based on the pattern of the thus obtained dried tear sample, whether the patient is at risk of or suffers from a neurocognitive disorder of the Alzheimer's disease spectrum.

traducir

Aβ BIOMARKER IN ALZHEIMER'S DISEASE MODEL MOUSE AND METHOD FOR ANALYZING SAME

NºPublicación: WO2023002967A1 26/01/2023

Solicitante:

SHIMADZU CORP [JP]
UNIV TOKYO [JP]

Resumen de: WO2023002967A1

An AD model mouse-derived biological sample is subjected to detection of markers including mouse Aβ1-40 and mouse APP669-711, the respective measurement levels for mouse Aβ1-40 and mouse APP669-711 in the biological sample are obtained, and the ratio APP669-711/Aβ1-40 of the mouse APP669-711 level to the mouse Aβ1-40 level is obtained. If the aforementioned ratio for the AD model mouse is higher than the aforementioned ratio for a reference mouse in which brain Aβ accumulation is absent, the brain Aβ accumulation amount in the AD model mouse is determined to be higher than the brain Aβ accumulation amount in the reference mouse.

traducir

METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

NºPublicación: WO2023004054A1 26/01/2023

Solicitante:

MEMORIAL SLOAN KETTERING CANCER CENTER [US]
MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES [US]
SLOAN KETTERING INST CANCER RES [US]

Resumen de: WO2023004054A1

The present technology relates to methods for treating, preventing, and/or ameliorating Alzheimer's disease, in a subject in need thereof. In particular aspects, the present technology relates to the use of MAPK inhibitors to treat, prevent, and/or ameliorate Alzheimer's disease.

traducir

COMPONENT ASSAY FOR ALZHEIMER'S DISEASE IN A LIVING SUBJECT

NºPublicación: WO2023004096A1 26/01/2023

Solicitante:

CASSAVA SCIENCES INC [US]

Resumen de: WO2023004096A1

A method of assaying for the presence of Alzheimer's disease (AD) in a living human subject using a serum or plasma sample preparation from that human subject is disclosed. In one aspect, the presence of an about 90 kDa filamin A (FLNA) polypeptide fragment in a sample preparation indicates that the sample donor likely had AD. More preferably, a ratio of the amount of that about 90 kDa FLNA polypeptide fragment to the amount of full length (about 280 kDa) FLNA protein in the sample preparation is determined. If that ratio is about 10 to about 2000, the donor likely had AD, whereas if that ratio is about 0.005 to about 5, the donor likely did not have AD. A method for determining the treatment prognosis of a living human subject presumed to have Alzheimer's disease (AD), a system and kit for carrying out the assays are also contemplated.

traducir

COMPOSITIONS AND METHODS THAT ATTENUATE COGNITIVE AGING IN INDIVIDUALS WHO DO NOT HAVE DEMENTIA

NºPublicación: US2023028607A1 26/01/2023

Solicitante:

NESTLE SA [CH]

JP_2022172152_A

Resumen de: US2023028607A1

A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid, a nitric oxide releasing compound, Vitamin B12 and choline. The composition is administered in a daily dose that provides 0.1 to 50 times the recommended daily requirement (RDA) of Vitamin B12 per day, more preferably 0.1 to 40 times the recommended daily requirement (RDA) of Vitamin B12 per day and 0.01 to 10.0 times the recommended daily requirement (RDA) of choline. Optionally Vitamin B6 and/or Vitamin B9 can be included in the composition. The method can achieve a benefit that is one or more of decreasing brain atrophy, increasing or maintaining number of synapses, increasing amyloid-β phagocytosis, or decreasing or maintaining neuroinflammation in the non-demented individual. The method can prevent dementia in an individual at risk thereof, for example an elderly human.

traducir

PERIPHERAL BLOOD TCR MARKER OF ALZHEIMER'S DISEASE, AND DETECTION KIT AND APPLICATION THEREOF

NºPublicación: WO2023000688A1 26/01/2023

Solicitante:

CHENGDU EXAB BIOTECHNOLOGY CO LTD [CN]

CN_113567682_A

Resumen de: WO2023000688A1

A peripheral blood TCR marker of Alzheimer's disease, and a detection kit and application thereof. The peripheral blood TCR marker of Alzheimer's disease comprises at least one of proteins of which sequences are as shown in SEQ ID NOs. 1-50. On the basis of a high-throughput sequencing method, only a small amount of peripheral blood needs to be collected for extracting RNA, an immune map library is established by treating samples, and then upon high-throughput sequencing and TCR data analysis, a characteristic TCR sequence in the peripheral blood of Alzheimer's disease is firstly determined, and then a test result of a sample to be tested is compared with the characteristic TCR sequence, so as to determine whether a person suffers from Alzheimer's disease. According to the method, a huge number of specific TCR sequences of Alzheimer's disease can be compared at the same time, and compared with the detection of one or more markers alone, the marker has higher specificity and accuracy, and the diagnosis efficiency is improved.

traducir

SYSTEMS AND METHODS OF DETECTING A RISK OF ALZHEIMER'S DISEASE USING A CIRCULATING-FREE MRNA PROFILING ASSAY

NºPublicación: EP4121553A1 25/01/2023

Solicitante:

MOLECULAR STETHOSCOPE INC [US]

AU_2021236680_PA

Resumen de: WO2021188825A1

Disclosed herein are panels related to the diagnosis of diseased tissue in a subject. The disclosed panels and related methods are used to predict or assess whether a subject has a neurodegenerative disorder taking into account the age of the subject. Some embodiments of the methods include applying a gene filter based on the age of the subject and generating an output of gene expression data which takes into account differences in gene profiles seen in tissues as they age.

traducir

BLOOD-BASED ASSAY FOR DIAGNOSING AND TREATING BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION

NºPublicación: US2023017557A1 19/01/2023

Solicitante:

WASHINGTON UNIVERSITY ST LOUIS [US]

JP_2022547209_A

Resumen de: US2023017557A1

The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues, using blood samples, to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

traducir

NEURODEGENERATIVE DISEASE MARKER AND APPLICATION THEREOF

NºPublicación: WO2023284035A1 19/01/2023

Solicitante:

SHENZHEN INST ADV TECH [CN]

CN_115612728_PA

Resumen de: WO2023284035A1

A neurodegenerative disease marker and an application thereof. The neurodegenerative disease marker comprises a cystatin C coding gene NM_009976.4. It is found for the first time that the expression of cystatin C coding gene in Alzheimer disease brain tissue (cortex, hippocampus, and synapse) is down-regulated, but the level of cystatin C protein in the peripheral serum of Alzheimer disease is increased, and therefore, early diagnosis of Alzheimer disease can be performed by measuring the indicators.

traducir

ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF

NºPublicación: AU2022252753A1 19/01/2023

Solicitante:

ABL BIO INC [KR]

MX_2020004674_A

Resumen de: AU2022252753A1

The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody.

traducir

BIOMARKERS FOR ALZHEIMER'S DISEASE

NºPublicación: WO2023285462A1 19/01/2023

Solicitante:

FONDAZIONE ST ITALIANO TECNOLOGIA [IT]
FOND SANTA LUCIA [IT]

Resumen de: WO2023285462A1

Disclosed are N-acylphosphatidylethanolamine (NAPE) molecules as biomarkers for Alzheimer's disease (AD), the use thereof in a method for the diagnosis or prognosis of AD, and a kit for implementation of the method.

traducir

CROSS-LINKED PRODUCT OF AMYLOID-B PROTEIN (AB) AS POTENTIAL SUBSTITUTE FOR AMYLOSPHEROIDS (ASPD) AND ANALYSIS OF ASPD

NºPublicación: US2023021187A1 19/01/2023

Solicitante:

FOUNDATION FOR BIOMEDICAL RES AND INNOVATION AT KOBE [JP]

CN_114729932_A

Resumen de: US2023021187A1

A substance that can be a substitute for amylospheroids (ASPD) and a method for analyzing ASPD are provided. Viewed from one aspect, the present disclosure relates to a substance in which amyloid-β protein (Aβ) is cross-linked with a cross-linking agent that has a spacer arm length of between 4 Å and 50 Å inclusive or a cross-linking agent that has, as a spacer arm, not less than 1 and not more than 13 groups that are an oxyethylene group(s) (—CH2CH2O—) and/or an oxypropylene group(s) (—CH2CH2CH3O—). Viewed from another aspect, the present disclosure relates to a method for analyzing ASPD using the substance as a reference material.

traducir

DIAGNOSTIC METHODS USING PGC-1Α EXPRESSION

NºPublicación: EP4118435A1 18/01/2023

Solicitante:

BIORCHESTRA CO LTD [KR]

KR_20220154772_PA

Resumen de: WO2021181364A1

The present disclosure relates to the use of PGC-1α expression to identify a subject that is conducive to treatment with a miR-485 inhibitor. In some aspects, the subject suffers from a disease or disorder associated with reduced PGC-1α expression. In some aspects, the PGC-1α expression is measured in the serum of the subject.

traducir

DIAGNOSTIC METHODS USING SIRT1 EXPRESSION

NºPublicación: EP4118436A1 18/01/2023

Solicitante:

BIORCHESTRA CO LTD [KR]

KR_20220155585_PA

Resumen de: WO2021181365A1

The present disclosure relates to the use of SIRT1 expression to identify a subject that is conducive to treatment with a miR-485 inhibitor. In some aspects, the subject suffers from a disease or disorder associated with reduced SIRT1 expression. In some aspects, the SIRT1 expression is measured in the serum of the subject.

traducir

DEVICES, KITS, AND METHODS FOR DETERMINING INCREASED SUSCEPTIBILITY TO AND TREATMENT AND PREVENTION OF PERIODONTITIS, ALZHEIMER'S DISEASE, AND OTHER CONDITIONS

NºPublicación: WO2023283021A1 12/01/2023

Solicitante:

LEVINE MARTIN [US]

Resumen de: WO2023283021A1

Diagnostic microarray devices, kits, and methods of treating or reducing the occurrence of various conditions or diseases are disclosed, wherein the conditions or diseases include (but are not limited to) periodontal disease, Alzheimer's disease, cardiovascular disease, arthritis, and adverse pregnancy outcomes. The devices, kits, and methods utilize an analysis of single nucleotide polymorphisms (SNPs) from various interleukins.

traducir

BIOMARKERS FOR ALZHEIMER'S DISEASE TREATMENT

NºPublicación: WO2023283650A1 12/01/2023

Solicitante:

EISAI R&D MAN CO LTD [JP]
SWANSON CHAD [US]

Resumen de: WO2023283650A1

Disclosed herein are method of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.

traducir

METHOD FOR THE DETECTION OF APOLIPOPROTEIN E4

NºPublicación: JP2023002599A 10/01/2023

Solicitante:

シュピーンゴテックゲゼルシャフトミットベシュレンクテルハフツング

US_2021223242_A1

Resumen de: EP3309550A1

The present invention provides a method for the detection of Apolipoprotein E isotype 4 (ApoE4) or fragments thereof in a blood sample of a subject, whereby said method comprises the steps of contacting said sample with a solid phase, contacting said sample with at least one binder binding specifically to ApoE4 or a fragment thereof, thereby forming an ApoE4binder-complex, and detecting the ApoE4-binder-complex.

traducir

CSF-BASED PROGNOSTIC BIOMARKERS IN ALZHEIMER'S DISEASE AND METHODS OF USE THEREOF

NºPublicación: US2023003744A1 05/01/2023

Solicitante:

UNIV RUTGERS [US]
UNIV EMORY [US]

Resumen de: US2023003744A1

Embodiments of the disclosure are directed to biomarkers, or a panel of biomarkers, that determine progression of Alzheimer's disease, and methods of use thereof.

traducir

MARKER OF ALZHEIMER'S DISEASE AND USE THEREOF

NºPublicación: WO2023272576A1 05/01/2023

Solicitante:

SHENZHEN INST OF ADV TECH CAS [CN]

Resumen de: WO2023272576A1

Provided in the present application is a marker of Alzheimer's disease, which marker comprises monocyte chemoattractant protein-1 (MCP 1). Further provided in the present application are a method for detecting the marker of Alzheimer's disease, a kit for detecting Alzheimer's disease, and the use of the marker, the detection method and the kit in the screening of a drug for treating Alzheimer's disease.

traducir

SCREENING METHOD OF THERAPEUTIC AGENT FOR BRAIN DISEASES

NºPublicación: WO2023277459A1 05/01/2023

Solicitante:

HUSCION CO LTD [KR]

KR_20230001825_PA

Resumen de: WO2023277459A1

The present invention relates to a screening method of a therapeutic agent for brain diseases. Specifically, the screening method according to the present invention can be useful for screening a therapeutic agent for brain diseases. The screening method is based on the fact that Rg3, which is known to have a therapeutic effect for Alzheimer's disease, promotes NF-κB signaling mechanisms while promoting M2 polarization and suppressing M1 polarization, suppresses Aβ accumulation by increasing SRA protein expression, and suppresses water-soluble APPα processing in neural cells through water-soluble APPα generation and the suppression of Aβ42 generation by increasing ADAM10 protein expression in microglia or neuroblastoma.

traducir

METHODS FOR QUANTIFICATION OF AMYLOID BETA PEPTIDES IN PLASMA BY MASS SPECTROMETRY

NºPublicación: KR20230002465A 05/01/2023

Solicitante:

아라클론바이오테크에스엘

CN_115427815_A

Resumen de: WO2021219917A1

The present invention relates to a method for preparing a plasma sample comprising amyloid beta peptides for analysis by mass spectrometry, comprising the steps of: a) placing said plasma sample in contact with a denaturing agent, b) performing a first solid phase extraction step on the solution obtained in step a) to recover a first eluate, c) performing a second solid phase extraction step on said first eluate obtained in step b) to recover a second eluate, and d) drying said second eluate obtained in step c) and processing it for analysis by mass spectrometry, wherein the solution obtained in step d) comprises intact amyloid beta peptides Aß40 and Aß42.

traducir

MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS

NºPublicación: US2023003721A1 05/01/2023

Solicitante:

DAVIS RONALD L [US]
LIU ZE [US]
VARKUTI BOGLARKA H [HU]
KEPIRO MIKLOS [HU]
MACMULLEN COURTNEY M [US]
THE UNIV OF FLORIDA RESEARCH FOUNDATION INC [US]

WO_2021113127_A2

Resumen de: US2023003721A1

Described herein is a multiplexed and high content screening assay using primary neurons for identifying small molecule modulators of neuronal mitochondrial mitostasis (MnMs). Also described is a high throughput screening assay using primary neurons for identifying small molecules that increase mitochondrial function, identified by measuring the electrochemical potential across the inner mitochondrial membrane and ATP generation. Most MnMs that increased mitochondrial content, length and/or health also increased mitochondrial function without altering neurite outgrowth. Some MnMs protect mitochondria in primary neurons from Aβ(1-42) toxicity, glutamate toxicity, increased oxidative stress and the toxic cellular environment associated with Alzheimer's disease. Some MnMs target mitochondria directly. An MnM also increases the synaptic activity of hippocampal neurons and is potent in vivo, increasing the respiration rate of brain mitochondria after administering the compound to mice. The MnMs were demonstrated to protect the mitochondrial population in neurons in an in vivo model of Alzheimer's Disease. Also described is a method for treating a patient suffering from a disorder characterized by dysfunction of neuronal mitostasis, comprising administering to the patient a therapeutically effective amount of a compound (MnM), or a pharmaceutically acceptable salt thereof.

traducir

PROTEIN MARKERS FOR ASSESSING ALZHEIMER'S DISEASE

NºPublicación: IL298100A 01/01/2023

Solicitante:

UNIV HONG KONG SCIENCE & TECH [HK]

AU_2021273299_PA

Resumen de: WO2021228125A1

The present invention provides protein markers present in a person's blood sample (such as a plasma, serum, or whole blood sample) that are associated with the Alzheimer's Disease (AD), diagnostic and treatment methods for AD, and kits for diagnosing AD.

traducir

Silver Nanoneedles for Sustained DC Current Single Nanopore Measurements

NºPublicación: US2022412949A1 29/12/2022

Solicitante:

UNIV CINCINNATI [US]

Resumen de: US2022412949A1

A composition having one or more nanoneedles is provided, where each nanoneedle has a silver tip and one or more of the silver tips comprise an AgCl layer. In one approach, one or more of the silver tips further include a layer of thiol-polyethylene glycol. A method of resistive pulse detection involving a protein pore is also provided. The method involves reconstituting one or more protein pores in a lipid membrane formed on the tip of a nanoneedle, then applying a potential across the membrane and detecting resistive pulses.

traducir

COROSOLIC ACID CAPABLE OF IMPROVING INSULIN RESISTANCE/SENSITIVITY AND ENHANCING METABOLIC FUNCTION AND ANALOGUE THEREOF

Nº publicación: WO2022270112A1 29/12/2022

Solicitante:

MATSUYAMA FUTOSHI [JP]

Resumen de: WO2022270112A1

[Abstract] Corosolic acid improves insulin resistance and recovers an insulin function that is deteriorated with age. As a result, the insulin sensitivity in an aged person is improved and the metabolism in all cells gets active. [Problem] The problem to be solved by the present invention is to alleviate and ameliorate an adult disease, a lifestyle-related disease, dementia and the like associated with insulin resistance and achieve a long healthy life-span by corosolic acid and an analogue thereof. There is a finding about a composition which recovers a function inherent to insulin again against the slowing down of an insulin reaction or insulin resistance that is believed as a main cause of an adult disease, a lifestyle-related disease, dementia or the like and is consequently useful for the delay of progression or prevention of an adult disease, a lifestyle-related disease, dementia/Alzheimer's disease or the like, and an idea about a specific method is proposed.

traducir

Página1 de 2 nextPage por página

punteroimgVolver